A Phase 1 interventional study of BI 1815368 and Itraconazole in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the effect on the exposure of BI 1815368 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Further exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were administered during Period 1 on Day 1/Visit 2 a single oral dose of BI 1815368 tablet with 240 milliliters (ml) of water following an overnight fast of at least 10 hours (h) as reference treatment R. On Days -3 to 6/Visit 3 of Period 2, subjects were administered a 20 mL (200 mg) oral solution of itraconazole with 240 mL of water after an overnight fast of at least 9 hours once daily for 9 days (9 doses in total). On Day 1/Visit 3 of this period, they received a single oral dose of BI 1815368 tablet with 240 mL of water following an overnight fast of at least 10 hours (h). This combined treatment constituted the test treatment T. The BI 1815368 single doses of Treatments R (Visit 2) and T (Visit 3) were separated by a washout period of at least 7 days.
Drug: BI 1815368 · Drug: Itraconazole
BI 1815368
Itraconazole
Also known as: Sempera®
Area Under the Concentration-time Curve of BI 1815368 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
Time frame: Within 3 hours prior to and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 34, 47, and 71 hours for both periods, and additionally at 95, 119 and 143 hours for Period 2 after BI 1815368 administration.
Maximum Measured Concentration of BI 1815368 in Plasma (Cmax)
Maximum measured concentration (Cmax) of BI 1815368 in plasma is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.
Time frame: Within 3 hours prior to and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 34, 47, and 71 hours for both periods, and additionally at 95, 119 and 143 hours for Period 2 after BI 1815368 administration.
Area Under the Concentration-time Curve of BI 1815368 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.
Time frame: Within 3 hours prior to and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 34, 47, and 71 hours for both periods, and additionally at 95, 119 and 143 hours for Period 2 after BI 1815368 administration.
This study was an open-label, single-center, two-period, fixed-sequence trial in healthy male subjects. Each subject participated in two treatment periods (Days -3 to 4 in Period 1 and Days -3 to 7 in Period 2) and received the Reference treatment (R) in Period 1 and the Test treatment (T) in Period 2.
| Milestone | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Started | 14 |
| Completed | 14 |
| Not completed | 0 |
| Milestone | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Started | 14 |
| Completed | 14 |
| Not completed | 0 |
| Milestone | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Started | 14 |
| Completed | 13 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
| nanomoles*hour/Liter (nmol*h/L) | BI 1815368 (R) Alone | Itraconazole and BI 1815368 (T) |
|---|---|---|
| Area Under the Concentration-time Curve of BI 1815368 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 3876.73 ± NA | 8178.83 ± NA |
Maximum measured concentration (Cmax) of BI 1815368 in plasma is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.
| nanomoles/Liter (nmol/L) | BI 1815368 (R) Alone | Itraconazole and BI 1815368 (T) |
|---|---|---|
| Maximum Measured Concentration of BI 1815368 in Plasma (Cmax) | 704.47 ± NA | 847.84 ± NA |
Area under the concentration-time curve of BI 1815368 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included 'subjects' as a random effect and treatment as a fixed effect. These quantities were then back transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.
| hour*nanomole/Liter | BI 1815368 (R) Alone | Itraconazole and BI 1815368 (T) |
|---|---|---|
| Area Under the Concentration-time Curve of BI 1815368 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 3850.70 ± NA | 8133.88 ± NA |
Collected over BI 1815368 alone: From drug administration of BI 1815368 in period 1 until 4 days after treatment administration. Itraconazole alone: From first drug administration of itraconazole in period 2 until drug administration of BI 1815368, up to 4 days. BI 1815368 and itraconazole: From first drug administration of BI 1815368 in period 2 until 8 days after last treatment administration of itraconazole in period 2, up to 14 days. All-cause mortality was recorded until end of trial, up to 23 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 1815368 (R) Alone | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Itraconazole Alone | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Itraconazole and BI 1815368 (T) | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Event | BI 1815368 (R) Alone | Itraconazole Alone | Itraconazole and BI 1815368 (T) |
|---|---|---|---|
| HeadacheNervous system disorders | 4/14 | 0/14 | 3/13 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 2/14 | 1/13 |
| FatigueGeneral disorders | 1/14 | 0/14 | 0/13 |
| Upper respiratory tract infectionInfections and infestations | 1/14 | 0/14 | 0/13 |
The treated set (TS) included all subjects who were treated with at least 1 dose of trial drug.
| Age, Continuous(Years) | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Mean | 39.6 ± 9.3 |
| Sex: Female, Male(Participants) | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Female | 0 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | BI 1815368 (R), Then Itraconazole and BI 1815368 (T) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Aug 2023 to primary completion in Oct 2023, 2 months.
Results were first posted in May 2026, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI 1815368